ArticleClinical epigenetics2026
Mechanistic studies of molecular networks associated with pulmonary hypertension explored by combined transcriptome analysis of Project-methylation.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgoundPulmonary hypertension (PH) is characterized by pulmonary vascular remodeling, which ultimately leads to right heart failure. Previous studies have confirmed that DNA variations contribute to the development and progression of PH. This study aims to integrate methylation and transcriptome data to uncover key molecular networks and potential therapeutic targets for PH.
methodsGene expression (GSE117261) and methylation data (GSE84395) from PH patients were retrieved from the GEO database. Differential genes and methylation sites were identified using the limma and ChAMP packages. A co-expression network was constructed using WGCNA, and the functions of key genes were explored through immune infiltration analysis, GSEA/GSVA pathway enrichment, transcriptional regulatory network prediction, and experimental validatio.
resultsSeven key genes (S100A9, IL18RAP, CXCR2, LCN2, INHBA, CSF3R, LTBP1) were identified. Among these, CXCR2 was significantly upregulated in both PH patients and animal models. Bioinformatics analysis revealed that CXCR2 drives pulmonary vascular remodeling via multiple pathways, including the IL-17 signaling pathway (inflammatory reaction), ROS pathway (oxidative stress), PI3K/AKT/mTOR pathway (cell proliferation), and metabolic pathways. Experimental validation confirmed high expression of CXCR2 in the smooth muscle layer of pulmonary arteries and its strong association with immune cell infiltration (neutrophils, monocytes).
conclusionThrough multi-omics integration analysis, this study elucidates the key molecular mechanisms underlying PH and identifies potential therapeutic targets. In the pathogenesis of PH, dysfunction of inflammatory and immune responses plays a critical role. Experimental validation demonstrates that CXCR2 may serve as a novel biomarker and therapeutic target for PH, with its multi-pathway regulatory mechanism providing a theoretical foundation for precision medicine in PH treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.